. Author manuscript; available in PMC: 2015 Mar 19.

Published in final edited form as: Pathol Oncol Res. 2014 Jun 3;21(1):167–172. doi: 10.1007/s12253-014-9802-x

Table.

Final Diagnosis of 15 Cases in Which Cytologic and Histologic Discordance Observed

			IHC^a
Case No.	Cytologic Diagnosis	Histologic Diagnosis	TTF-1	p63	Final Diagnosis
9	NSCLC-NOS	Fav AC	Neg	3+	SqCC
14	Fav AC	Fav SqCC	Neg	3+	SqCC
15	AC	Fav SqCC	Neg	3+	SqCC
18	Fav AC	Fav SqCC	3+	3+	AC
21	Fav AC	Fav SqCC	Neg	3+	SqCC
22	Fav AC	NSCLC-NOS	Neg	3+	SqCC
27	Fav SqCC	NSCLC-NOS	3+	3+	AC
28	Fav SqCC	Fav AC	3+	3+	AC
29	AC	Fav SqCC	Neg	3+	SqCC
46	Fav AC	SqCC	Neg	3+	SqCC
49	Fav AC	NSCLC-NOS	Neg	3+	SqCC
79	Fav AC	NSCLC-NOS	Neg	3+	SqCC
80	Fav AC	SqCC	Neg	3+	SqCC
97	AC	SqCC	Pearl formation		SqCC
109	Fav SqCC	Fav AC	3+	3+	AC

Abbreviations: AC, adenocarcinoma; fav, favor; IHC, immunohistochemistry; Neg, negative; NSCLC-NOS, non–small cell lung carcinoma, not otherwise specified; SqCC, squamous cell carcinoma, TTF-1, thyroid transcription factor-1.

3+ indicates strong immunostain observed in more than 50% of tumor cells.